Our Programs

Pipeline

Our development programs represent the potential to improve the well-being of people whose lives are currently limited by rare disease.

BioCryst Pharmaceuticals discovers novel, oral small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease. Our lead development program is BCX10013*, a potentially once-daily, oral Factor D inhibitor for the treatment of complement-mediated diseases.

BioCryst’s discovery team is also designing oral drug candidates for additional targets in the classical, lectin and terminal pathways of complement.

For inquiries about licensing opportunities, please contact our business development group.

Program
  • Lead Optimization

  • Pre-clinical

  • EARLY DEVELOPMENT

  • PIVOTAL

  • Approved / Commercial

Phase
Hereditary Angioedema (HAE)
ORLADEYO® (berotralstat)
Oral Plasma Kallikrein Inhibitor
Approved / Commercial
Complement-Mediated Diseases
BCX10013 – Oral Factor D Inhibitor
EARLY DEVELOPMENT
Oral Drugs for Complement (Targets Undisclosed)
Lead Optimization
infectious diseases
RAPIVAB® (peramivir injection)
Approved / Commercial

*BCX10013 is investigational and has not been deemed safe and effective by the FDA.